Angina Pectoris - Drug Pipeline Landscape, 2023

Angina Pectoris - Drug Pipeline Landscape, 2023

Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.

Angina is caused due to the built up of plaque in the arteries. The major risk factors that are concerned with angina are smoking, age, stress, lack of physical activity, family history of premature cardiovascular diseases. Medical conditions that exacerbate angina are diabetes, dyslipidaemia, hypertension, kidney disease, polycythaemia, and it is also concerned with the use of medications such as vasodilators.

Symptoms that are associated with angina are chest pain or discomfort. Pain around epigastrium, neck, shoulders and back. Autonomic symptoms include nausea, vomiting, pallor, shortness of breath, squeezing and fatigue.

Angina can be diagnosed with the primary complains including chest pain or discomfort, chest tightness and precipitated by cold weather or a meal. Electrocardiogram is recommended to determine the ST elevations. Non-invasive testing includes coronary angiogram. Imaging testing includes echocardiogram, CT and MRI.

Angina treatment is aimed at providing sufficient oxygen supply to the heart. Common treatment options include anticoagulants, nitrates or calcium channel blocker, beta-blockers and statins. Angioplasty and sometimes coronary artery bypass grafting are recommended in severe disease condition. Lifestyle changes promotes towards healthier condition.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Angina Pectoris treatment such as Ad5FGF-4, AR36, ACP-01 and others. Key players involved in the development of therapies to treat Angina Pectoris are Azurity Pharmaceuticals, Gene Biotherapeutics, Hemostemix Inc, Milestone Pharmaceuticals Inc, XyloCor Therapeutics Inc, and others. Two drugs are under late-stage Phase III clinical trials and four drugs are in Phase II clinical trials and some other drugs are under Phase I, Preclinical and Discovery stages of development.

Report Highlights

Global Insight Service's, Angina Pectoris - Drug Pipeline Landscape, 2023 report provides an overview of the Angina Pectoris pipeline drugs. This report covers detailed insights on Angina Pectoris drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Angina Pectoris pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Angina Pectoris - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Angina Pectoris
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Angina Pectoris - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1 Ad5FGF-4
5.1.2 AR36
5.2 Clinical Stage Drugs - Phase II
5.2.1 ACP-01
5.2.2 BJY-802
5.2.3 Ninerafaxstat
5.2.4 XC001
5.3 Clinical Stage Drugs - Phase I
5.3.1 CKD-385
5.4 Early-Stage Drugs - Preclinical
5.4.1 Etripamil
5.5 Early-Stage Drugs - Discovery
5.5.1 CR-0202
5.5.2 CR-0305
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Azurity Pharmaceuticals
9.2 Chong Kun Dang Holdings Corp
9.3 Coeurative Inc
9.4 Eight Plus One Pharmaceutical Co Ltd
9.5 Gene Biotherapeutics
9.6 Hemostemix Inc
9.7 Imbria Pharmaceuticals Inc
9.8 Milestone Pharmaceuticals Inc
9.9 XyloCor Therapeutics Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Angina Pectoris
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - Ad5FGF-4/Gene Biotherapeutics
Table 2.2 Clinical Trial Details - BJY-802/Eight Plus One Pharmaceutical Co Ltd
Table 2.3 Clinical Trial Details - Ninerafaxstat/Imbria Pharmaceuticals Inc
Table 2.4 Clinical Trial Details - XC001/XyloCor Therapeutics Inc
Table 2.5 Clinical Trial Details - CKD-385/Chong Kun Dang Holdings Corp
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
List of Figures
Figure 1.1 Number of Products under Development for Angina Pectoris, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Angina Pectoris, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Angina Pectoris, 2023
Figure 1.4 Products by Top 5 Molecule Type for Angina Pectoris, 2023
Figure 1.5 Products by Top 5 Route of Administration for Angina Pectoris, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings